Xerostomia (dry mouth) therapeutics market is projected to grow at a considerable CAGR of 7% during the forecast period (2019-2025). As per the American Dental Association, the rate of prevalence of xerostomia in the general population ranges from 0.9% to 64.8%. Severance of xerostomia leads to a critical impact on the patient’s health and quality life as it causes oral discomfort to the patient. The rise in the prevalence of Sjogren’s syndrome along with an increase in the consumption of medications is a major factor to drive the growth of the global xerostomia therapeutics market. As per the Association, the prevalence of xerostomia is considered 100% in patients with Sjogren’s syndrome or patients who have undergone radiation therapy for head and neck cancer.  

According to the Rare Genomics Institute, Sjogren’s syndrome is the third most common autoimmune disorder, behind rheumatoid arthritis and systemic lupus erythematosus. It is the common disorder amongst females that account for 90% of all Sjogren Syndrome cases. This syndrome affects individuals between the ages of 40 to 60. The US witnessed 0.2 million to 3 million cases related to Sjogren's syndrome per year. 

Few of the studies exhibit that the incidence of the Sjogren's syndrome ranges between 3 and 6 per 100,000 every year. Therefore, the rising prevalence of Sjogren's syndrome is anticipated to drive the demand of xerostomia therapeutics market across the globe. Apart from the growing cases of Sjogren's syndrome, the rising geriatric population across the globe, increasing prevalence of chronic diseases, and the growing awareness about the diagnosis and treatment of xerostomia are further anticipated to promote the growth of the global xerostomia therapeutics market. 

Further, with the increase in the prevalence of diseases such as cancer, and HIV the demand for radiation and chemotherapy which in turn leads to xerostomia. Chemotherapy treatment makes saliva thicker that leads to dry mouth condition. Lack of awareness among peoples related to the xerostomia and the availability of ineffective treatment of xerostomia in the developing countries across the globe is a key factor that is likely to restrain the global xerostomia therapeutics market during the forecast period. 

Segmental Outlook 

The xerostomia (dry mouth) therapeutics market is segmented on the basis of product type. Based on product type market is segmented into artificial saliva, dentifrices, salivary stimulants, saliva substitutes, drugs, and salivary pen. Based on type, the market is segmented into prescription and OTC. Based on Product, artificial is anticipated to hold considerable market share during the forecast period. Artificial saliva is designed to moisten and offers relief in pain and discomfort from the severe dry mouth syndrome. This is due to the fact that the reduction of saliva in the mouth leads to mouth infections, an altered sense of taste or smell, tooth decay, and many other problems. Different artificial saliva works in a different manner some last for up to 2 hours and some last up to 12 hours. Therefore, the growing requirement of artificial saliva to moisturize mouth is anticipated to drive the growth of the segment

Global Xerostomia Therapeutics Market Share by Product Type, 2018 (%)

Regional Outlook 

The global xerostomia therapeutics market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America held the major share in the market in 2018. The regional growth is attributed to the increasing healthcare expenditure in the US and the presence of well-developed healthcare infrastructure in the country. 

Global Xerostomia Therapeutics Market Growth, by Region 2019-2025

Asia-Pacific will augment with the significant growth rate in the xerostomia therapeutics market 

The major economies contributing to the regional growth of the market include China, Japan, and India. The increasing healthcare expenditure along with the rising prevalence of diseases, such as diabetes, HIV, diabetes, cancer, and Parkinson’s disease that cause dry mouth conditions are the key factors that are driving the growth of the xerostomia therapeutics market. According to the WHO, 1 in 15 people dies due to cancer in India every year. Chemotherapy is a common procedure used for the treatment of cancer. Therefore, the rising prevalence of cancer in India is promoting therapies such as chemo which in turn is driving the growth of the market in the region as these therapies are the most common cause of xerostomia.

Market Players Outlook

Some of the key players in the xerostomia therapeutics market include GlaxoSmithKline Plc, Church & Dwight Co., Inc., Colgate-Palmolive Co., Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma Group Plc, Quest Products, LLC (OraCoat), EUSA Pharma NP, and so on. These market players adopted various organic and inorganic growth strategies such as mergers and acquisitions and product launches in order to expand their share in the market and gain a competitive advantage over other players. For instance, in February 2016, Hikma Pharmaceuticals acquired Roxane Laboratories to expand its product portfolio in the oral care segment. 

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global xerostomia therapeutics market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.